APREMILAST

Brand name:

• Otezla®

Pharmaceutical company:

Amgen Australia Pty Limited

Condition/indication:
(therapeutic use)

• Severe chronic plaque psoriasis

PBAC Submission type:

Change to listing (–)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – May 2022

Related medicines:

• APREMILAST

Submission received for:

May 2022 PBAC meeting

Opportunity for consumer comment:

Open 24/11/2021 and close 27/01/2022 (see PBS Website)

PBAC meeting:

Held on 06/05/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

30/05/2022

Lodgement of required documentation:

04/06/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 14/06/2022

Status:

Finalised

Government processes:

Commenced on 14/06/2022

Medicine listed on the PBS:

01/09/2022 (see PBS schedule)

---